18F-FDG PET/CT usefulness vs Tc99m-Tetrofosmin in the assessment of malignant brain gliomas: Report of two cases

Document Type: Case Report

Authors

1 Nuclear Medicine Unit, University of Bari “Aldo Moro”, Bari, Italy

2 Pathological Anatomy Unit, University of Bari “Aldo Moro”, Bari, Italy

Abstract

Gliomas account for almost 80% of primary malignant brain tumors in adults. Magnetic Resonance imaging (MRI) is still the gold standard for diagnosis of brain tumors and brain 99mTc-tetrofosmin Single Photon Emission Computed Tomography (99mTc-tetrofosmin-SPECT) has been established as a useful tool for their evaluation. Fluorine-18–2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) provides non-invasive information for staging, clinical assessment and prognosis of glial tumors. We report 2 cases of patients with brain lesions described on MRI suspected for malignancy, however 99mTc-tetrofosmin-SPECT that didn’t show any lesion, 18F-FDG PET/CT revealed radiotracer uptake that supported the hypothesis of malignant gliomas, confirmed later by biopsy. Our cases confirm 18F-FDG PET/CTmay be useful for differentiating common enhancing malignant brain tumors and is recommended when differential diagnoses are difficult to narrow using MRI and 99mTc-tetrofosmin-SPECT. 18F-FDG PET/CT can be used to characterize their aggressiveness and to detect a more feasible site for a stereotaxic biopsy. It yields supplementary non-invasive information to conventional imaging useful in the clinical decision-making.

Keywords

Main Subjects


Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006 Sep;2(9):494-503.

Arbizu J, Domínguez PD, Diez-Valle R, Vigil C, García-Eulate R, Zubieta JL, Richter JA. Neuroimaging in brain tumors. Rev Esp Med Nucl. 2011 Jan-Feb;30(1):47-65.

Alexiou GA, Tsiouris S, Vartholomatos G, Fotakopoulos G, Papadopoulos A, Kyritsis AP, Voulgaris S, Fotopoulos AD. Correlation of glioma proliferation assessed by flow cytometry with (99m)Tc-Tetrofosmin SPECT uptake. Clin Neurol Neurosurg. 2009 Dec;111(10):808-11.

Herholz K, Langen KJ, Schiepers C, Mountz JM. Brain tumors. Semin Nucl Med. 2012 Nov;42(6):356-70.

Pardo FS, Aronen HJ, Fitzek M, Kennedy DN, Efird J, Rosen BR, Fischman AJ. Correlation of FDG-PET interpretation with survival in a cohort of glioma patients. Anticancer Res. 2004 Jul-Aug;24(4):2359-65.

Alexiou GA, Tsiouris S, Kyritsis AP, Fotakopoulos G, Goussia A, Voulgaris S, Fotopoulos AD. The value of 99mTc-tetrofosmin brain SPECT in predicting survival in patients with glioblastoma multiforme. J Nucl Med. 2010 Dec;51(12):1923-6.  

Choi JY, Kim SE, Shin HJ, Kim BT, Kim JH. Brain tumor imaging with 99mTc-tetrofosmin: comparison with 201Tl, 99mTc-MIBI, and 18F-fluorodeoxyglucose. J Neurooncol. 2000;46(1):63-70.

Kläsner BD, Krause BJ, Beer AJ, Drzezga A. PET imaging of gliomas using novel tracers: a sleeping beauty waiting to be kissed. Expert Rev Anticancer Ther. 2010 May;10(5):609-13.

Hustinx R, Smith RJ, Benard F, Bhatnagar A, Alavi A. Can the standardized uptake value characterize primary brain tumors on FDG-PET? Eur J Nucl Med. 1999 Nov;26(11):1501-9.

Kosaka N, Tsuchida T, Uematsu H, Kimura H, Okazawa H, Itoh H. 18F-FDG PET of common enhancing malignant brain tumors. AJR Am J Roentgenol. 2008 Jun;190(6):W365-9. 

Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol. 1987 May;22(5):360-71.

Niccoli Asabella A, Altini C, Pisani AR, Ingravallo G, Rubini G. 18F-FDG PET/CT metabolic activity assessment in infective and neoplastic diseases: a patient with systemic hydatidosis and concomitant Burkitt lymphoma. Clin Nucl Med. 2013 Jul;38(7):546-9.